Modiblast mode of action

Dendritic cells of leukemic origin (DCleu) are induced by the combined action of a maturation cytokine, granulocyte-macro-phage colony stimulation factor (GM-CSF), and a „danger signal“, prostaglandin E1 (PGE1).

This combination has been found by experimentation based on previously published protocols for DC generation.

DCleu carry the antigens of the blasts they are derived from, so they can present these antigens to a variety of immune cells. They stimulate a broad anti-leukemic response that involves both innate and adaptive immune cells.

Modiblast treatment has been shown to upregulate B cells, killer T cells and other immune cells and to reduce regulatory cells.

By triggering the patient’s immune system in this way, residual blast cells can be eliminated.

In comparison to active immunotherapies, a specific advantage of the Modiblast protocol is the generation of a functional immunological memory.